Source Code Capital

Source Code Capital is a research-driven Beijing-based venture firm with a thesis centered on industrial digitization and biotech, including high-conviction positions in AI-enabled chemistry and life sciences platforms. The firm distinguishes itself through a deeply analytical sourcing model that produces concentrated thematic positions rather than diversified portfolio bets.

The healthcare-relevant thesis spans biotech, AI and machine learning applied to healthcare, and life sciences tools. Source Code Capital has notably backed Chemical.AI, a platform automating chemical synthesis through machine learning, which illustrates the firm’s appetite for foundational AI plays in life science workflows. The broader healthcare strategy treats AI-native platforms in chemistry and biology as enabling infrastructure for the next generation of therapeutic development.

The firm writes $5M to $25M checks across Seed, Series A, Series B, and Growth, with stage coverage that lets it accompany high-conviction companies across multiple rounds. Geographic focus is China, with portfolio companies routinely operating across global markets when commercial dynamics require it. Founders should expect serious technical diligence on AI capabilities and underlying scientific defensibility before any investment proceeds.

The team operates a research-led investment model that produces deep sector positioning before deal flow rather than reactive sourcing from inbound channels. Specific partner names are not provided in the source data, and founders should engage through the firm’s English-language website and expect to be routed to the partner whose expertise aligns with the underlying technology.

The approach is concentrated and research-driven. Source Code Capital invests where it has built thematic conviction through internal research and is willing to commit serious capital and ownership to high-conviction positions. The firm is a strong fit for AI-native biotech and life science tooling founders building defensible technical platforms with meaningful China exposure. Founders building broad horizontal software or operating without a clear technical edge may find the fund’s research-driven approach a poor structural match.